|
Post by Casey on Feb 11, 2009 12:03:34 GMT -5
|
|
|
Post by Casey on Feb 11, 2009 12:21:06 GMT -5
Sorry, one more thing to add to my earlier post. Allon Therapeutics announces milestones for 2009 VANCOUVER — January 12, 2009 - Allon Therapeutics Inc. (TSX: NPC) announced today its 2009 milestones and confirmed that the Company’s existing cash resources are sufficient to fund its business into 2011. While Allon continues partnership negotiations in AD, it will move forward with a Phase II clinical trial in frontotemporal dementia (FTD). FTD describes several cognitive disorders, such as Pick’s disease, for which no treatment is currently available, including several that are fatal within three to five years of diagnosis. In addition, about 50% of the FTD disorders are tauopathies, or tau-related diseases. Allon’s technology is recognized as the most clinically advanced tau-related therapy. The Company believes that there are regulatory routes to achieve an approval with FTD in a much shorter timeframe than AD, while moving forward concurrently with a partner in AD. The whole article can be found at the link below. www.allontherapeutics.com/ir_news_Jan12_2009.html
|
|